Merck Says US FDA Approves Keytruda Qlex Subcutaneous Injection
MT Newswires Live
Sep 22
Merck (MRK) said Monday the US Food and Drug Administration has approved Keytruda Qlex subcutaneous injection for treating adults with solid tumors.
The company said the injection is approved for 38 indications and can be administered in one minute every three weeks or two minutes every six weeks.
The drugmaker said the approval was based on a phase 3 trial showing comparable efficacy and safety to intravenous Keytruda.
Keytruda Qlex is expected to be available in the US from late September, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.